UNION: 3y EFS 91% vs 77% with SCRT/CAPOX/camrelizumab vs long-course CRT/CAPOX in rectal cancer. HR 0.33 (95% CI 0.15-0.71). Impressive signal. But RT schedule and IO both changed, so this doesn't isolate the benefit of either. #ESMO26 #radonc https://t.co/IU5gid4jyS https://t.co/8GwAXPEpzH